奥瑞珠单抗治疗的多发性硬化患者对新冠疫苗的体液与T细胞应答
这项单中心研究纳入112名参与者,评估奥瑞珠单抗治疗的多发性硬化患者接种BNT162b2疫苗后的SARS-CoV-2特异性抗体和T细胞反应。结果显示,患者T细胞反应与健康对照相当,但抗体滴度和阳性率显著较低,且与末次输注时间正相关。
要点
- 奥瑞珠单抗治疗患者T细胞反应与健康对照相当(89.7% vs 100%)。
- 患者抗体阳性率明显低于健康对照和未治疗患者(25%-40.8% vs 100%)。
- 抗体阳性率与末次奥瑞珠单抗输注时间呈正相关。
核心结论
- 奥瑞珠单抗治疗的多发性硬化患者接种BNT162b2后T细胞反应与健康对照相当,但抗体反应较低。
研究设计与样本
- 单中心研究,在以色列耶路撒冷Hadassah医疗中心进行,纳入49例奥瑞珠单抗治疗的多发性硬化患者、23例未治疗患者和40例健康对照,均接种2剂BNT162b2疫苗。
主要发现
- 奥瑞珠单抗组29例中26例(89.7%)和健康对照15例中15例(100%)在接种后产生SARS-CoV-2特异性T细胞,水平相似(均值[SD]分别为15.4[7.6]和14.3[6.3]斑点形成细胞)。
- 奥瑞珠单抗组S1/S2抗体阳性率为10/40(25%),受体结合域抗体阳性率为20/49(40.8%),均低于健康对照和未治疗患者的100%。
- 抗体阳性率与末次奥瑞珠单抗输注时间呈正相关(S1/S2:r=0.7,P<.001;受体结合域:r=0.4,P=.04)。
临床怎么用
- 奥瑞珠单抗治疗的多发性硬化患者接种新冠疫苗后仍可产生T细胞反应,可能有助于预防重症。
- 临床决策时可考虑疫苗接种时机与奥瑞珠单抗输注间隔的关系。
局限性
- 单中心研究,样本量有限;T细胞评估仅在部分参与者中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: B-cell-depleting therapies may affect the development of a protective immune response following vaccination. Understanding the ability to develop vaccine-specific immunity to COVID-19 in patients with multiple sclerosis (MS) treated with B-cell-depleting therapy is of importance for clinical decisions. OBJECTIVE: To assess SARS-CoV-2 vaccine-specific humoral and cellular responses in patients treated with ocrelizumab compared with healthy controls. DESIGN, SETTING, AND PARTICIPANTS: This single-center study performed at Hadassah Medical Center in Jerusalem, Israel, included patients with MS treated with ocrelizumab, healthy controls, and untreated patients with MS. Vaccination occurred between December 2020 and April 2021. Participants donated blood 2 to 4 and 2 to 8 weeks after the second vaccine dose for antibody and T-cell assessments, respectively. EXPOSURES: All participants received 2 doses of BNT162b2 vaccine (Pfizer/BioNTech) and completed the study. MAIN OUTCOMES AND MEASURES: Proportion of patients treated with ocrelizumab with SARS-CoV-2-specific serology and/or T-cell responses following vaccination. All participants underwent SARS-CoV-2 antibody testing; 29 patients treated with ocrelizumab and 15 healthy controls had evaluation of SARS-CoV-2-specific T-cell responses. RESULTS: Of 112 participants, 49 (43.8%) had MS and were treated with ocrelizumab (33 [67.3%] female; mean [SD] age, 47.9 [13.3] years), 23 (20.5%) had MS and were not treated with disease-modifying therapies (18 [78.3%] female; mean [SD] age, 49 [13.4] years), and 40 (35.7%) were healthy controls (25 [62.5%] female; mean [SD] age, 45.3 [16] years). Twenty-six of 29 patients (89.7%) treated with ocrelizumab and 15 of 15 healthy controls (100%) had SARS-CoV-2-specific T cells following vaccination at similar levels (mean [SD], 15.4 [7.6] and 14.3 [6.3] spot-forming cells, respectively). Mean antibody titers and positive serology rate were lower in the group of patients treated with ocrelizumab (mean [SD] antibody titers and positive serology rate, 26.2 [49.2] and 376.5 [907.6] AU/mL; 10 of 40 [25%] and 20 of 49 [40.8%] for S1/S2 and receptor-binding domain, respectively) compared with healthy controls (mean [SD] antibody titers and positive serology rate, 283 [100] and 12 712 [9114] AU/mL; 100% S1/S2 and receptor-binding domain) and untreated patients (mean [SD] antibody titers and positive serology rate, 288.3 [113.8] and 10 877 [9476] AU/mL; 100% S1/S2 and receptor-binding domain), with positive association to time from ocrelizumab infusion (S1/S2: r = 0.7, P < .001; receptor-binding domain: r = 0.4, P = .04). CONCLUSION AND RELEVANCE: In this study, patients with MS who were treated with ocrelizumab generated comparable SARS-CoV-2-specific T-cell responses with healthy controls and had lower antibody response following vaccination. Given the potential role of T cells in protection from severe disease, this is reassuring and will help physicians develop consensus guidelines regarding MS treatment in the era of the COVID-19 pandemic.
引用
- Brill L, Rechtman A, Zveik O, et al. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 2021. PMID: 34554197. doi:10.1001/jamaneurol.2021.3599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。